Leukemic Stem Cells Shows the Way for Novel Target of Acute Myeloid Leukemia TherapyAdhra Al-Mawali*
Director of Research and Studies. Directorate of Research and Studies, Directorate General of Planning, Ministry of Health, PO Box 393, PC 111, Muscat, Sultanate of Oman
- *Corresponding Author:
- Adhra Al-Mawali PhD
Director of Research and Studies. Directorate of Research and Studies
Directorate General of Planning, Ministry of Health
PO Box 393, PC 111, Muscat, Sultanate of Oman
Tel: +968 24697551
Fax: +968 24696702
E-mail: [email protected], [email protected]
Received date: July 23, 2013; Accepted date: September 18, 2013; Published date: September 20, 2013
Citation: Al-Mawali A (2013) Leukemic Stem Cells Shows the Way for Novel Target of Acute Myeloid Leukemia Therapy. J Stem Cell Res Ther 3:151. doi:10.4172/2157-7633.1000151
Copyright: © 2013 Al-Mawali A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Leukemic stem cells (LSCs) have been identified in acute myeloid leukemia (AML). Similar to haematopoietic stem cells, these LSCs are able to self-renew, differentiate, and proliferate extensively. Recent studies suggest that LSCs are critical for the initiation and maintenance of leukemia. This review will describe the characteristic features of LSCs in AML and the possible targets expressed on the surface of AML, the intracellular targets and the novel molecular and flow cytometry methodologies being used to particularly ablate the LSC population. Studies have shown the potential importance of ablating LSCs when treating leukemia. The unique characteristics of LSCs that differentiate them from their normal counterparts can be applied to specifically target the leukemic population. Current therapeutic strategies may not effectively ablate the LSCs, leaving the potential for disease progression or recurrence. A better understanding of LSCs and molecular biology will allow the design of more effective therapies.